Fifty 1 Labs Plans $1 Million R&D Financing Initiative Over the Next 6 to 8 Weeks

Proceeds expected to support peptide discovery, preclinical work, regulatory planning, AI infrastructure, and telehealth development

VANCOUVER, British Columbia – August 18, 2026 - Fifty 1 Labs, Inc. (OTCID: FITY) today announced its intention to pursue approximately $1 million in research and development funding over the next six to eight weeks, subject to market conditions, investor interest, regulatory requirements, and applicable securities laws.

The Company expects that any successfully raised funds would be used to support its peptide biotechnology and health-sciences strategy. Potential uses include scientific consultants and personnel, peptide synthesis and analytical testing, formulation and delivery feasibility studies, stability and impurity testing, preclinical pharmacology and toxicology planning, CRO and CDMO fees, regulatory consulting, protocol development, intellectual-property work, AI-enabled discovery infrastructure, and other operating needs.

A portion of the funds may also be allocated to the Company's planned U.S. telehealth peptide services platform, including telehealth software, medical-record systems, clinician contracting and onboarding, patient intake workflows, pharmacy-partner integration, laboratory coordination, compliance systems, adverse-event reporting processes, cybersecurity, insurance, and patient-support infrastructure.

"Capital efficiency will be central to our strategy," said Joel J. Gagnier, Ph.D., MSc, N.D., Chief Executive Officer of Fifty 1 Labs. "We intend to use R&D funding to support the highest-value milestones first: selecting credible peptide development candidates, establishing the right external partnerships, building the infrastructure needed for quality and compliance, and positioning the Company for future financing, partnerships, and regulatory engagement."

The Company intends to maintain flexibility over the allocation of proceeds based on the amount raised, candidate-selection results, regulatory feedback, partner interest, and management's assessment of development priorities. There can be no assurance that the Company will raise the targeted amount, complete any financing on acceptable terms, use proceeds as currently planned, or achieve revenue or profitability.

This announcement is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. Any offering of securities would be made only through appropriate offering documents and in compliance with applicable federal and state securities laws.

In a previous announcement, Fifty 1 Labs provided an overview of its planned U.S.-focused telehealth peptide services platform. The Company intends to develop a patient-facing service model that complements its peptide science and commercialization strategy while remaining separate from investigational clinical-development programs.

About Fifty 1 Labs, Inc.
Fifty 1 Labs, Inc. is a biotechnology and health-sciences company focused on peptide products, peptide sciences, AI-enabled discovery, musculoskeletal health, sports recovery, and planned U.S. telehealth peptide services. The Company's strategy includes R&D, partnerships, potential acquisitions, clinical-development planning, and commercialization pathways where legally permissible.

Contact:
Investor Relations
Fifty1 Labs, Inc.

ir@fifty1labs.com | (877) 505-5006
www.fifty1labs.com

Forward-Looking Statements

Safe Harbor Statement:

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, identified by words such as “may,” “will,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, involve risks and uncertainties that could cause actual results to differ materially from those projected. Such risks include, but are not limited to, general economic conditions, competition, technological changes, and other factors detailed in the company’s Disclosure Statements. The company undertakes no obligation to update these statements.